Medlive Technology Co Ltd

Medlive Technology Co Ltd maintains a strong liquidity position, with a current ratio of 19.09 and cash and equivalents amounting to CNY 2.57 billion, which significantly exceeds its total liabilities of CNY 293.48 million. The company's price-to-book ratio is 1.23, and its price-to-tangible-book ratio is also 1.23, indicating a relatively modest premium over its book value. The debt-to-equity ratio is 0.0, reflecting a capital structure that is entirely equity-funded. In terms of profitability, the company's return on equity (ROE) is 6.87%, and its return on assets (ROA) is 6.48%, both of which are strong indicators of efficient use of equity and assets. The operating margin is 56.15% (calculated as operating income of CNY 360.84 million divided by revenue of CNY 642.16 million), and the net profit margin is 52.07% (calculated as net income of CNY 334.34 million divided by revenue of CNY 642.16 million), suggesting a highly profitable business model. The company's revenue is concentrated in a single segment, as no segmental breakdown is provided in the available data. Geographically, the company's exposure is not specified, but its operations are primarily in the health care technology sector. The company's revenue for the latest period is CNY 642.16 million, and while no prior period data is provided, the strong net income and operating income suggest a stable revenue stream. The company's outlook for the current fiscal year is positive, with a mean price target of CNY 11.73 and a median price target of CNY 11.40, both above the current market price of CNY 8.08. Analysts have issued two strong-buy and two buy recommendations, with no hold or sell ratings, indicating a favorable sentiment toward the stock. The company's risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The absence of long-term debt and the high cash reserves further support the low liquidity risk profile. No dilution sources were identified in the available data, and the number of shares outstanding has not changed between basic and diluted shares, suggesting no near-term dilution pressure. Recent events and filings do not provide specific details, but the company's strong financial performance and positive analyst sentiment suggest a stable and growing business.